Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Most claims are about IV solutions and therapeutic uses/general effects of dextrose and sodium chloride, but the provided FDA label excerpts are for oral potassium chloride extended-release tablets indicated for hypokalemia; those IV-solution composition/vehicle claims are not supported by the supplied label material.
Category Scores
Accurate Statements
Potassium chloride is added to IV fluids to correct or prevent potassium deficiency (hypokalemia).
The provided label excerpts support potassium chloride for the treatment and prophylaxis of hypokalemia (oral potassium chloride extended-release tablets), but do not specifically support IV fluid composition or administration.
The described IV solution contains potassium chloride at 0.075%.
No matching label excerpt provided regarding IV solution concentration or formulation.
Unsupported Statements
The described IV solution contains potassium chloride at 0.075%.
The supplied FDA excerpts are for potassium chloride extended-release tablets (oral) and do not describe any IV solution or that concentration.
The described IV solution contains dextrose at 10%.
No label excerpt provided describing an IV formulation containing 10% dextrose (context of dextrose only appears in the hyperkalemia treatment section for overdose, not as a described IV product composition).
The described IV solution contains sodium chloride at 0.45%.
No label excerpt provided describing an IV formulation containing sodium chloride at 0.45%.
Dextrose (glucose) is used to treat or prevent low blood sugar levels.
Not supported by the provided excerpts.
In IV solutions, dextrose can serve as a vehicle for other medications.
Not supported by the provided excerpts.
Sodium chloride is essential for maintaining fluid balance in the body.
Not supported by the provided excerpts.
IV solutions containing sodium chloride can help rehydrate patients.
Not supported by the provided excerpts.
IV solutions containing sodium chloride can correct electrolyte imbalances.
Not supported by the provided excerpts.
IV solutions containing sodium chloride can serve as a base for administering other drugs.
Not supported by the provided excerpts.
Potassium chloride is added to IV fluids to correct or prevent potassium deficiency (hypokalemia).
The label excerpts support potassium chloride for treatment/prophylaxis of hypokalemia, but do not support IV fluid addition or that specific IV context.
Contradictions
Important Omissions
No mention (or verification) that the actual FDA-approved dosage form discussed in the label is potassium chloride extended-release tablets (oral) and includes specific administration instructions (e.g., take with meals, swallow whole) and monitoring guidance for serum potassium.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are largely about IV solution composition and general therapeutic roles of dextrose/sodium chloride, which are not substantiated by the provided label excerpts. No direct dosing/contraindication misuse is explicitly proposed in the claims provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Claims about IV solution formulation (0.075% KCl, 10% dextrose, 0.45% NaCl) and general uses/roles of dextrose and sodium chloride are not supported by the supplied FDA label excerpts for oral potassium chloride extended-release tablets.
Suggested Improvement
Restrict evaluation statements to the label-supported indication (treatment/prophylaxis of hypokalemia), dosing ranges, and monitoring/administration instructions for potassium chloride extended-release tablets. Avoid asserting IV composition or general IV-solution properties unless the provided FDA label excerpts explicitly describe them.